Rochester Drug Cooperative, Inc.

United States Bankruptcy Court, W.D. New York·Decided September 11, 2020·No. 2-20-20230·Unknown

Opinion

UNITED STATES BANKRUPTCY COURT WESTERN DISTRICT OF NEW YORK _________________________________________

In re:

Rochester Drug Cooperative, Inc., Bankruptcy Case No. 20-20230-PRW Chapter 11

Debtor. _________________________________________

DECISION AND ORDER DENYING MOTIONS TO COMPEL PRODUCTION OF DOCUMENTS, GRANTING CROSS-MOTION TO QUASH SUBPOENAS AND DEFERRING REQUEST OF HEALTH PLAN INSURERS FOR SANCTIONS UNDER RULE 45(d)(1) FRCP

PAUL R. WARREN, U.S.B.J.

“There are books of which the backs and covers are by far the best parts.”1 So, it can be said about the motions presently occupying the Court’s attention. The motions have very little to do with this Chapter 11 case and very much to do with class action lawsuits, concerning the ravages caused by opioids, pending in dozens of district courts around the country. A group of Private Insurance Class Action Claimants (“Class Claimants”) have moved under Rule 9016 FRBP and Rule 45 FRCP for an order compelling Empire Healthcare HMO, Inc., Humana Health Company of New York, Inc. and Aetna Health Inc. (“Insurers” collectively) to compel the production of documents related to the influence of opioid abuse on health insurance premiums.2 The Insurers oppose the motions, requesting that the subpoenas be quashed and that sanctions be imposed against the Class Claimants.

1 Charles Dickens, Oliver Twist Ch. 14 (Richard Bentley 1838). 2 The Court will deal with the three motions to compel production in a single decision. The motions are identical and the Insurers filed a single, joint response to the motions. For the reasons that follow, the motions of the Class Claimants (ECF Nos. 596, 597, 598) are DENIED. The cross-motion of the Insurers to quash the subpoenas (ECF No. 667) is GRANTED. The request of the Insurers for the imposition of sanctions, under Rule 45(d)(1) FRCP, is DENIED, without prejudice to the Insurers seeking relief from the United States District Court for the Northern District of Ohio, the Multi-District Litigation (“MDL”) court that

issued a stay of discovery in connection with In re National Prescription Opiate Litigation, No. 1:17-md-02804 (N.D. Ohio filed Feb. 21, 2020).

I. JURISDICTION The Court has jurisdiction under 28 U.S.C. §§ 157 and 1334. This is a core proceeding under 28 U.S.C. § 157(b)(2)(A), and possibly (O). Venue is proper under 28 U.S.C. §§ 1408 and 1409.

II. FACTS The facts framing the dispute before the Court are straightforward in direction and few in number. On July 1, 2020, the Class Claimants filed a motion seeking leave to file a class Proof of Claim. (ECF No. 465). While that motion was awaiting a hearing, on July 6, 2020, the Class Claimants issued subpoenas to the Insurers (non-debtor third parties), demanding the production of documents. (ECF Nos. 596, Ex. A; 597, Ex. A; 598, Ex. A). The motion concerning the filing of a class Proof of Claim was resolved by a Stipulation and Order, filed on July 31, 2020. (ECF No. 567). On August 10, 2020, the Class Claimants filed a Proof of Claim with the Court- appointed claims agent. (See Claim No. 22454 at https://dm.epiq11.com/case/rochesterdrugcoop/claims (last visited Sept. 11, 2020)). Attached to the Proof of Claim is a 27-page “Addendum” describing the basis for the claim, as well as a copy of a 122-page Class Action Complaint filed with the United States District Court for the Northern District of Illinois. In their Proof of Claim, the Class Claimants readily acknowledge that “[b]y

order Dated December 14, 2017 (as supplemented by orders dated January 11, 2018 and February 16, 2018), U.S. District Judge Dan Aaron Polster imposed a stay in the MDL against prosecution of almost all opioid-related litigation (including the Private Insurance Class Actions), except for certain bellweather cases.” (Id. at Addendum ¶ 54). As a result, “Private Insurance Plaintiffs have been precluded from conducting discovery because of the stay imposed in connection with the MDL.” (Id. at Addendum ¶ 55). The day after filing the Proof of Claim, the Claims Claimants filed motions to compel the production of documents by each of the Insurers. (ECF Nos. 596, 597, 598, 606, 607, 608). The Class Claimants did not seek leave to conduct an examination under Rule 2004 FRBP prior to issuing the subpoenas. Neither was there any litigation pending (in this

Court) involving the Class Claimants and the Insurers, either in the form of an adversary proceeding or contested matter. The Insurers jointly filed lengthy opposition to the motions to compel production. (ECF No. 667). In a nutshell, the Insurers assert five grounds upon which the subpoenas should be quashed: (1) the subpoenas were issued without authority because they do not relate to a contested matter; (2) the Class Claimants did not seek permission to conduct an examination under Rule 2004 FRBP; (3) the legal theory of the Class Claimants is flawed; (4) the subpoenas are overbroad and unduly burdensome; and (5) the subpoenas seek confidential trade secrets. (Id. ¶¶ 4-8). The Insurers request that sanctions be imposed against the Class Claimants, under Rule 45(d)(1) FRCP. III. ISSUE The question presented is whether a creditor has the right to issue a subpoena to a non- debtor third-party, under Rule 45 FRCP and Rule 9016 FRBP, where the creditor simply files a

Proof of Claim, but neither requests leave to conduct an examination under Rule 2004 nor is party to an adversary proceeding or party to a contested matter being litigated. The answer is no.

IV. DISCUSSION A. The Subpoenas Must Be Quashed As Improperly Issued

Free access — add to your briefcase to read the full text and ask questions with AI

Rochester Drug Cooperative, Inc., (N.Y. 2020).

Rochester Drug Cooperative, Inc. (Rochester Drug Cooperative, Inc.) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Procedures
28 U.S.C. § 157
§ 1334
28 U.S.C. § 1334
§ 1409
28 U.S.C. § 1409